Creative Medical Technology Holdings, Inc. (CELZ)
- Previous Close
4.3200 - Open
4.7600 - Bid --
- Ask --
- Day's Range
4.3300 - 4.7600 - 52 Week Range
3.9300 - 10.2812 - Volume
6,197 - Avg. Volume
214,709 - Market Cap (intraday)
6.024M - Beta (5Y Monthly) 5.05
- PE Ratio (TTM)
-- - EPS (TTM)
-3.7600 - Earnings Date Aug 9, 2024 - Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
www.creativemedicaltechnology.comRecent News: CELZ
Performance Overview: CELZ
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CELZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CELZ
Valuation Measures
Market Cap
5.87M
Enterprise Value
-4.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
677.23
Price/Book (mrq)
0.57
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.49%
Return on Equity (ttm)
-40.34%
Revenue (ttm)
9k
Net Income Avi to Common (ttm)
-5.29M
Diluted EPS (ttm)
-3.7600
Balance Sheet and Cash Flow
Total Cash (mrq)
9.99M
Total Debt/Equity (mrq)
0.14%
Levered Free Cash Flow (ttm)
-6.37M
Research Analysis: CELZ
Company Insights: CELZ
CELZ does not have Company Insights